The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 01, 2012

Filed:

Jun. 07, 2007
Applicants:

Yusheng Wu, New York, NY (US);

Ulrich Iserloh, Hoboken, NJ (US);

Jared N. Cumming, Garwood, NJ (US);

Xiaoxiang Liu, River Vale, NJ (US);

Robert D. Mazzola, Stewartsville, NJ (US);

Zhong-yue Sun, Parlin, NJ (US);

Ying Huang, East Brunswick, NJ (US);

Andrew Stamford, Chatham Township, NJ (US);

Brian Mckittrick, New Vernon, NJ (US);

Zhaoning Zhu, Plainsboro, NJ (US);

Inventors:

Yusheng Wu, New York, NY (US);

Ulrich Iserloh, Hoboken, NJ (US);

Jared N. Cumming, Garwood, NJ (US);

Xiaoxiang Liu, River Vale, NJ (US);

Robert D. Mazzola, Stewartsville, NJ (US);

Zhong-Yue Sun, Parlin, NJ (US);

Ying Huang, East Brunswick, NJ (US);

Andrew Stamford, Chatham Township, NJ (US);

Brian McKittrick, New Vernon, NJ (US);

Zhaoning Zhu, Plainsboro, NJ (US);

Assignee:

Schering Corporation, Kenilworth, NJ (US);

Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07D 239/20 (2006.01); C07D 239/22 (2006.01); A61K 31/497 (2006.01); A61K 31/513 (2006.01); A61K 31/506 (2006.01); A61P 9/00 (2006.01); A61P 25/28 (2006.01); A61P 31/18 (2006.01); C07D 495/20 (2006.01); A61K 31/527 (2006.01);
U.S. Cl.
CPC ...
Abstract

Disclosed are compounds of formula I or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, U, W, X, R, R, R, R, Rand Rare as described above in the specification. Also disclosed is the method of inhibiting aspartyl protease, and in particular, the methods of treating cardiovascular diseases, cognitive and neurodegenerative diseases. Also disclosed are methods of treating cognitive or neurodegenerative diseases using the compounds of formula I in combination with a cholinesterase inhibitor or a muscarinic magonist or mantagonist.


Find Patent Forward Citations

Loading…